Scilex Holding (SCLX) Non-Current Assets (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Non-Current Assets of $1.5 million for Q1 2026, up 1201.68% year-over-year from $119000.0 in Q1 2025, and up 196.18% quarter-over-quarter from $523000.0 in Q4 2025.
Scilex Holding (SCLX) Non-Current Assets (2020 - 2026) Analysis & Trends
Scilex Holding's Non-Current Assets history runs 7 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 1201.68% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 1201.68% YoY), while the FY2025 annual figure was $523000.0, up 339.5% from the prior year.
- Non-Current Assets for Q1 2026 stood at $1.5 million, up from $523000.0 in the prior quarter.
- The five-year high for Non-Current Assets was $141.7 million in Q2 2022, with the low at $119000.0 in Q4 2024.
- The 5-year median for Non-Current Assets is $944000.0 (2022), against an average of $23.6 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets slumped 99.89% in 2023, then soared 4814.46% in 2024.
- Scilex Holding's Non-Current Assets stood at $944000.0 in 2022, then retreated by 4.98% to $897000.0 in 2023, then sank by 86.73% to $119000.0 in 2024, then jumped by 339.5% to $523000.0 in 2025, then surged by 196.18% to $1.5 million in 2026.
- Business Quant data shows SCLX's Non-Current Assets at $1.5 million in Q1 2026, $523000.0 in Q4 2025, and $119000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.69 Bn | 631.94 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 469.96 Bn | 463.39 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 375.18 Bn | 368.04 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 303.14 Bn | 295.45 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 257.49 Bn | 252.59 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 236.49 Bn | 222.50 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 182.35 Bn | 179.17 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 106.06 Bn | 101.89 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Scilex Holding | 39.10 Mn | -73.69 Mn | 3.97 Mn | 1.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.55 Mn |
| Dec 31, 2025 | 523,000.00 |
| Sep 30, 2025 | 119,000.00 |
| Jun 30, 2025 | 119,000.00 |
| Mar 31, 2025 | 119,000.00 |
| Dec 31, 2024 | 119,000.00 |
| Sep 30, 2024 | 8.16 Mn |
| Jun 30, 2024 | 2.90 Mn |
| Mar 31, 2024 | 1.08 Mn |
| Dec 31, 2023 | 897,000.00 |
| Sep 30, 2023 | 166,000.00 |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 153,000.00 |
| Dec 31, 2022 | 944,000.00 |
| Sep 30, 2022 | 101.29 Mn |
| Jun 30, 2022 | 141.69 Mn |
| Mar 31, 2022 | 140.45 Mn |
| Dec 31, 2021 | 538,000.00 |
| Sep 30, 2021 | 139.41 Mn |
| Jun 30, 2021 | 139.41 Mn |